Mounjaro vs Wegovy: the real weight-loss showdown, and how to actually choose
Reviewed against published clinical trial data. Last updated July 2026.
Medically reviewed by Dr. Kaynat Khan, Endocrinology · Obesity Medicine
Quick answer
Mounjaro is tirzepatide (it works on two hunger hormones) and Wegovy is semaglutide (one). Both are used for weight loss, and tirzepatide tends to show more in trials. The right one depends on tolerance, availability, and cost, which a doctor decides with you.
Mounjaro vs Wegovy is the matchup that actually matters, because both are built for weight loss. Here is what separates them beyond the bigger number everyone quotes.
Unlike some comparisons where one drug is really a diabetes medicine, this is a clean head-to-head: both Mounjaro and Wegovy are used to help people lose weight. So the question is genuinely which one, not which is on-label.
Same goal, different engines
Wegovy is semaglutide and works on one hunger hormone, GLP-1. Mounjaro is tirzepatide and works on two, GLP-1 and GIP. Both quieten appetite and steady blood sugar; the extra target is why tirzepatide tends to show larger weight loss.
| Mounjaro | Wegovy | |
|---|---|---|
| Medicine | Tirzepatide | Semaglutide |
| How it is taken | Weekly injection | Weekly injection |
| Average weight loss | Up to about 22.5% (SURMOUNT-1) | 13.7%-15% |
| Mainly approved for | Type 2 diabetes and weight | Weight management |
| Common side effects | Nausea, diarrhea, stomach pain | Nausea, constipation, vomiting |
| In India | Launched in India in 2025, prescription-only. | Available in India, prescription-only. |
What the trials show
In trials, tirzepatide reached up to about 22.5% weight loss at the highest dose (SURMOUNT-1, NEJM 2022), versus roughly 15% for semaglutide (STEP 1, NEJM 2021). On average, tirzepatide edges it.
So how do you actually choose?
A bigger average in a trial is not a promise for your body. Some people tolerate one better than the other, and side effects, what is actually in stock, and cost all matter. The gap between them can be smaller in real life than on a slide. This is a decision for a doctor who knows your history.
Cost in India
Treat any price as a moving range. Generic semaglutide (the Wegovy molecule) launched in India in 2026, which can shift the relative cost (Pearce IP, 2026). A doctor helps you weigh cost against what actually suits you.
Both are real tools for weight. The bigger trial number is a starting point, not a verdict. The right medicine is the one that is right and safe for you.
If you are choosing between them, a short consult gives you a real answer for your body instead of a headline.
Common questions
Is Mounjaro or Wegovy better for weight loss?
In trials tirzepatide (Mounjaro) produced more weight loss than semaglutide (Wegovy), up to about 22.5% versus about 15%. But more on average is not automatically better for a given person, and a doctor decides what suits you.
What is the difference between Mounjaro and Wegovy?
Mounjaro is tirzepatide and works on two hunger hormones (GLP-1 and GIP); Wegovy is semaglutide and works on one (GLP-1). Both are weekly injections used for weight loss.
Which one causes more weight loss?
In head-to-head trial figures, tirzepatide reached up to about 22.5% and semaglutide about 15%. Real-world results vary with dose, tolerance, and habits, and the gap can be smaller in practice.
Are both Mounjaro and Wegovy available in India?
Yes. Mounjaro launched in India in 2025 and Wegovy followed. Both are prescription-only and need a doctor's assessment.
Which has fewer side effects?
Both cause mostly stomach-related side effects early on, such as nausea, that usually settle as the dose is raised slowly. Which you tolerate better is individual, and a doctor helps you manage it.
Sources
This article is general information, not medical advice. A doctor decides what is right for you in a consultation.